ArticleBMC women's health2025
Sentinel lymph nodes mapping in ovarian cancer- preliminary results from single cancer center study.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroudOvarian cancer is the most fatal of all gynecologic cancers. The need and role of pelvic and para-aortic lymphadenectomy in ovarian cancer patients with clinically normal nodes remains debated.
objectiveTo assess the accuracy of sentinel lymph node (SLN) mapping in patients with ovarian carcinoma.
methodsThis is a single cohort quality improvement study conducted from May 1, 2020 to Dec. 31, 2022 at a single institution. Patients undergoing surgery for newly diagnosed ovarian carcinoma of all stages were eligible. All patients were injected with methylene blue into the bilateral ovarian cortex, uterine horns and infundibulopelvic ligaments by the same surgeon, SLN mapping was performed followed by an immediate back-up systematic pelvic and para-aortic lymphadenectomy. Ultrastaging was performed on all SLNs that were negative on original H&E slides. Descriptive statistics were used.
resultsTwenty-nine patients were enrolled. The overall detection rate of SLN in ovarian cancer was 100%, sensitivity was 85.7%, false negative rate was 14.3%, and negative predictive value was 95.7%. The median number of SLNs removed per patient was 8 (range, 1-20) and the median total of lymph nodes removed was 34 (range, 6-66). SLNs were identified in the supra-mesenteric para-aortic basin in 90 (34%) and in the infra-mesenteric para-aortic basin in 86 (32.5%).
conclusionIn this preliminary study with a small sample size of 29 patients, intraoperative SLN mapping using methylene blue injection demonstrated a high detection rate and promising feasibility and accuracy for identifying lymph node metastases in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.